doi: 10.1161/CIRCULATIONAHA.106.620757
(Circulation. 2006;113:2166-2168.)
© 2006 American Heart Association, Inc.
Editorial |
Preventing Vascular Events Due to Elevated Blood Pressure
From the Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.
Correspondence to Salim Yusuf, Population Health Research Institute, McMaster University and Hamilton Health Sciences, 237 Barton St E, Hamilton, Ontario, L8L 2X2, Canada. E-mail yusufs@mcmaster.ca
Key Words: Editorials • heart failure • hypertension • prevention
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
Elevated blood pressure (BP) demonstrates a consistent, strong, and graded relationship across the entire spectrum at levels >110 mm Hg systolic with several cardiovascular disease outcomes including cardiovascular death, myocardial infarction (MI), stroke, heart failure, and renal dysfunction.1 The population attributable risk due to elevated BP is large and consistent in all ethnic groups and regions of the world.2,3 In many countries (eg, United States, Canada, and Japan), strokes (especially hemorrhagic strokes) have been declining, which can be attributed, to a significant extent, to better BP control, although other factors (eg, changing diets and social and economic circumstances) are also likely to be important.4 By contrast, over the last 2 or 3 decades, the prevalence of heart failure has been increasing5 despite the increase in the proportion of patients with hypertension receiving BP-lowering therapy. This overall picture masks a decrease in heart failure in younger individuals, which is more than counterbalanced by an increase in the elderly.5
Article p 2201
Undoubtedly, BP lowering reduces heart failure to a substantial degree, but the randomized trials that have generated this evidence have generally lasted usually for an average of 5 years.6 At first glance, a 5-year trial may seem to be of long duration, but in fact it represents a relatively short duration of treatment (because the average time of treatment in these trials before an event occurs is approximately half the duration of the trial, which is only &2.5 years) compared with the need for lifelong therapy over several decades. Over
This article has been cited by other articles:
 |
|
 |
|
  A. M. Davis, L. M. Vinci, T. M. Okwuosa, A. R. Chase, and E. S. Huang Cardiovascular Health Disparities: A Systematic Review of Health Care Interventions Med Care Res Rev, October 1, 2007; 64(5_suppl): 29S - 100S. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Rosendorff, H. R. Black, C. P. Cannon, B. J. Gersh, J. Gore, J. L. Izzo Jr, N. M. Kaplan, C. M. O'Connor, P. T. O'Gara, and S. Oparil REPRINT Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention Hypertension, August 1, 2007; 50(2): e28 - e55. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Rosendorff, H. R. Black, C. P. Cannon, B. J. Gersh, J. Gore, J. L. Izzo Jr, N. M. Kaplan, C. M. O'Connor, P. T. O'Gara, and S. Oparil Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention Circulation, May 29, 2007; 115(21): 2761 - 2788. [Full Text] [PDF]
|
|
|
|
 |
|
 Which Antihypertensive Best Prevents HF in Patients with High BP? Journal Watch Cardiology, June 1, 2006; 2006(601): 1 - 1. [Full Text]
|
|